Flow cytometric analysis of Mouse CD30 expression on ConA-treated C57BL/6 mouse splenocytes. C57BL/6 mouse splenocytes treated 72h with ConA were stained with either Alexa Fluor® 647 Armenian hamster IgG Isotype Control (Left panel) or Alexa Fluor® 647 Armenian hamster Anti-Mouse CD30 Antibody (Right panel) at 1.25 μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Alexa Fluor® 647 Armenian hamster Anti-Mouse CD30 Antibody (S-R714)
Alexa Fluor® 647 Armenian hamster Anti-Mouse CD30 Antibody (S-R714)
Price:
Regular price
$190.00 SGD
Regular price
Sale price
$190.00 SGD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Armenian hamster |
| Antigen | CD30 |
| Synonyms | Tumor necrosis factor receptor superfamily member 8; CD30L receptor; Lymphocyte activation antigen CD30; Tnfrsf8 |
| Location | Cell membrane |
| Accession | Q60846 |
| Clone Number | S-R714 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | FCM |
| Reactivity | Ms |
| Positive Sample | ConA-treated C57BL/6 mouse splenocytes |
| Purification | Protein G |
| Concentration | 0.2 mg/ml |
| Conjugation | Alexa Fluor® 647 |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1.25μl per million cells in 100μl volume | Ms |
Background
CD30 (TNFRSF8) is a 120 kDa type-I transmembrane glycoprotein of the tumor necrosis factor receptor superfamily, expressed on activated T and B cells, Reed–Sternberg cells of classical Hodgkin lymphoma, and anaplastic large-cell lymphoma, where it regulates proliferation, apoptosis, and NF-κB signaling through TRAF1/2/5 adaptor proteins upon trimerization with its ligand CD30L (CD153), and serves as the validated target for the antibody–drug conjugate brentuximab vedotin that delivers the antimicrotubule agent monomethyl auristatin E into CD30-positive malignant cells.
Picture
Picture
FC
